Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
Kushida K, Fukunaga M, Kishimoto H, Shiraki M, Itabashi A, Inoue T, Kaneda K, Morii H, Nawata H, Yamamoto K, Ohashi Y, Orimo H. Kushida K, et al. Among authors: morii h. J Bone Miner Metab. 2004;22(5):469-78. doi: 10.1007/s00774-004-0509-z. J Bone Miner Metab. 2004. PMID: 15316868 Clinical Trial.
Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T. Matsumoto T, et al. Among authors: morii h. Osteoporos Int. 2009 Aug;20(8):1429-37. doi: 10.1007/s00198-008-0816-7. Epub 2008 Dec 20. Osteoporos Int. 2009. PMID: 19101754 Free PMC article. Clinical Trial.
Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
Kitatani K, Nakatsuka K, Naka H, Miki T, Morii H, Nishizawa Y. Kitatani K, et al. Among authors: morii h. J Bone Miner Metab. 2003;21(4):217-24. doi: 10.1007/s00774-003-0412-z. J Bone Miner Metab. 2003. PMID: 12811626 Clinical Trial.
Effect and safety of intermittent weekly administration of human parathyroid hormone 1-34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment.
Miki T, Nakatsuka K, Naka H, Masaki H, Imanishi Y, Ito M, Inaba M, Morii H, Nishizawa Y. Miki T, et al. Among authors: morii h. J Bone Miner Metab. 2004;22(6):569-76. doi: 10.1007/s00774-004-0525-z. J Bone Miner Metab. 2004. PMID: 15490267 Clinical Trial.
Risk factors for osteoporosis in men.
Izumotani K, Hagiwara S, Izumotani T, Miki T, Morii H, Nishizawa Y. Izumotani K, et al. Among authors: morii h. J Bone Miner Metab. 2003;21(2):86-90. doi: 10.1007/s007740300014. J Bone Miner Metab. 2003. PMID: 12601572
566 results